PATENT CLAIM ANALYSIS

Application Number: 16188784
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-04
Patent Classification: ["549", "448000"]

Abstract:
The present application discloses an acid labile lipophilic molecular conjugate of cancer chemotherapeutic agents and methods for reducing or substantially eliminating the side effects of chemotherapy associated with the administration of a cancer chemotherapeutic agent to a patient in need thereof.

Claim (Index 31):
The pharmaceutical composition of  claim 18 , wherein the acid labile lipophilic molecular conjugate of  claim 18 , where the abeo-taxane conjugate is of the formula:

Metadata:
- Claim Count in Document: 2.0
- Percentile: 98.0
- Lexical Diversity: 1.16667
- Patent Class: 549.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15675399', '13856216', '13489247', '14217074', '15131318']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8505670646550629
- 35 USC 102 Novelty (BERT): 0.6080623461528123
- Combined Prediction Score: 0.8263165928048379
- Mean Citation Score: 569.79196
- Max Citation Score: 612.5234
- Similarity Product: 462.70853820259566

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test